Millions of Australians set to save big on this revolutionary treatment
By
Danielle F.
- Replies 6
Australian healthcare has seen several significant changes over the past few years.This time, it just received a significant boost for those managing one of the deadliest conditions affecting a vast number of Aussies.
Sidapvia, a diabetes medication hailed as a 'cutting edge' solution for the condition, has been added to the Pharmaceutical Benefits Scheme (PBS).
Its inclusion should bring financial relief and simplified treatment to those affected by this chronic condition.
Sidapvia is an innovative medication that combines two diabetes drugs into a single pill, making the management of the disease more straightforward.
'Diabetes is one of those life-long conditions that places a great burden on patients,' Dr Ted Wu, Director of the Royal Prince Alfred Hospital Diabetes Centre, said.
'They could be on three or four types of tablets for diabetes, and some of these are taken multiple times a day.'
However, Sidapvia changed it by requiring only one dose daily.
When paired with a healthy diet and regular exercise, Sidapvia could lower blood sugar levels.
The original cost of Sidapvia was $75 per month.
With its inclusion in the PBS, the price has lowered to $31.60 per month.
Concession card holders could save more, as the drug should cost $7.70 per month.
This is a significant development for the over one million Australians living with diabetes and counting.
Health Minister Mark Butler talked about the impact of Sidapvia with optimism.
'This is just another cutting-edge treatment that will make the lives of tens of thousands of diabetes patients in Australia better,' Minister Butler shared.
The addition of Sidapvia to the PBS was a testament to the government's commitment to supporting Australians with long-term health conditions.
Earlier this year, the PBS has also started subsidising Verzenio, a drug which can prevent the recurrence of high-risk breast cancer.
Blood cancer-fighting drugs Imbruvica and Venetoclax also became a part of the PBS last month, which let patients go into remission without the need for chemotherapy.
These price reductions are monumental steps in making disease treatment management more accessible for Australians.
It also underscored the PBs's role in ensuring that essential medications are affordable, regardless of the patient's economic status.
Key Takeaways
- The price of the diabetes treatment Sidapvia has been significantly reduced for Australians thanks to the Pharmaceutical Benefits Scheme (PBS).
- Sidapvia is a 'cutting edge' medication that combines two diabetes drugs into a single pill, simplifying the regimen for diabetes patients.
- The cost of Sidapvia will drop from $75 per month to $31.60 for general patients. Concession card holders may pay for the drug for $7.70.
- The reduction in price should improve the lives of the over one million Australians living with diabetes.